Barbara Boreen
Primary Care · Birmingham, ALNPI 1184851966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Novartis at 27.5% of the total. Reporting peaked in 2021 at $1,201 and has fallen 84.4% since, to $188 in 2024.
Across 214 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Abbott$439
- Johnson & Johnson$378
- Irhythm Technologies, Inc.$248
- Amgen$176
- Merck$175
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,637100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 68 | $1,000 |
| Abbott | 14 | $439 |
| Johnson & Johnson | 26 | $378 |
| Irhythm Technologies, Inc. | 13 | $248 |
| Amgen | 13 | $176 |
| Merck | 11 | $175 |
| Sanofi-aventis U.S. LLC | 8 | $150 |
| E.r. Squibb & Sons, L.L.C. | 8 | $142 |
| Esperion Therapeutics, Inc. | 7 | $129 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $115 |
| Chiesi USA, Inc. | 7 | $114 |
| AstraZeneca | 8 | $111 |
| Daiichi Sankyo Inc. | 3 | $69 |
| Boehringer Ingelheim | 3 | $47 |
| Elutia, Inc. | 1 | $40 |
| Medtronic | 2 | $40 |
| Pfizer | 2 | $33 |
| Astellas Pharma US Inc | 2 | $31 |
| Bard Peripheral Vascular, Inc. | 1 | $30 |
| Lantheus Medical Imaging, Inc. | 1 | $29 |
| AbbVie | 2 | $28 |
| Convatec Inc. | 2 | $25 |
| Veryan Medical Incorporated | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Daxor Corporation | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,637 in reported general payments places this provider in the 80th percentile of 159 primary care providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $10,619 |
| ClopidogrelClopidogrel Bisulfate | 51 | $419 |
| Atorvastatin Calcium | 17 | $284 |
| Metoprolol Succinate | 13 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $10,61914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 159 primary care providers in Alabama.
Other primary care in Birmingham
- Josh WarrenBirmingham$9K
- Jill AroraBirmingham$6K
- Bevin EllenbergBirmingham$5K
- Samantha WilliamsBirmingham$4K
- Joanna ReavesBirmingham$3K
- Anna MesserBirmingham$2K
- Hannah WuisanBirmingham$2K
- Tiffany LasernaBirmingham$2K
- Holly StraussBirmingham$2K
- Brooke LittleBirmingham$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.